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Abstract
Legal, financial and organizational challenges and the absence of coherent international guidelines and legal frameworks still 
discourage many genetic studies to share individual research results with their participants. Studies and institutions decid-
ing to return genetic results will need to design their own study-specific return policy after due consideration of the ethical 
responsibilities. The Cooperative Health Research in South Tyrol (CHRIS) study, a healthy cohort study, did not foresee the 
return of individual genomic results during its baseline phase. However, as it was expected that the follow-up phase would 
generate an increasing amount of reliable genetic results, an update of the return of research results (RoRR) policy became 
necessary. To inform this revision, an empirical study using mixed methods was developed to investigate the views of CHRIS 
research participants (20), local general practitioners (3) and the local genetic counselling service (1). During the interviews, 
three different examples of potential genetic results with a very diverse potential impact on participants were presented: breast 
cancer, Parkinson disease and Huntington disease. The CHRIS participants also completed a short questionnaire, collecting 
personal information and asking for a self-evaluation of their knowledge about genetics. This study made it clear that research 
participants want to make autonomous decisions on the disclosure or non-disclosure of their results. While the motivations 
for participants’ decisions were very diverse, we were able to identify several common criteria that had a strong influence 
on their choices. Providing information on these factors is crucial to enable participants to make truly informed decisions.
Keywords Unsolicited findings · Return of genetic research results · Genetic research · Research policy · Healthy cohort 
study
Introduction: background
Technical advancements and decreasing costs of exome 
and genome sequencing have led to their rapidly expand-
ing application in research and thus to the generation of an 
increasing amount of reliable genetic results. Within the 
scientific community, consensus is growing that individual 
research results, which are analytically valid and clinically 
actionable, should be shared with research participants 
(Knoppers et al. 2015; Budin-Ljosne et al. 2016; Mackley 
et al. 2017). Those results could come as unsolicited results 
that might arise during further research, and might also be 
communicated to participants (Ewuoso 2016; Souzeau et al. 
2016; Mackley et al. 2017) on the basis that it raises the pos-
sibility of enabling appropriate medical treatment and possi-
bly preventing serious illness (Steinsbekk and Solberg 2012; 
Christenhusz et al. 2013). Moving beyond a clinical justifi-
cation, sharing results shows appreciation for participants’ 
contribution (McGuire and Lupski 2010), can strengthen a 
trustful relationship between researchers and participants 
and could lead to an increase in willingness to participate in 
further research studies (Kaufman et al. 2008).
Importantly, empirical evidence demonstrates that most 
research participants not only want to have access to their 
results (Bollinger et al. 2012; Facio et al. 2013; Allen et al. 
2014; Middleton et al. 2016; Jamal et al. 2017; Yamamoto 
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et al. 2017, 2018), they might even feel deceived or betrayed 
if results are withheld (Dresser 2014). Based on these find-
ings, in order to respect participants’ autonomy, research-
ers must at least offer the results to research participants. 
However, this desire or right to know must be balanced with 
participants’ “right not to know”. Offering results must be 
done in a manner that respects this right not to know and 
desire not to be told about the genetic information even if it 
is clinically actionable (Andorno 2004; Domaradzki 2015; 
Hofmann 2016). To truly respect the autonomy of the par-
ticipant in this domain, the final decision on actual disclo-
sure must always remain with the participant, who should 
have the possibility to decide what kind of results they want 
to receive (Angrist 2011; Budin-Ljøsne 2012).
There are, however, a number of challenges in the feed-
back of results. First, within the scientific community, there 
is a lack of consensus on the results to be returned. Some 
estimates locate the potential number of genetic variants 
meeting the threshold for disclosure today between 11,000 
and 15,000 (Cassa et al. 2012). The American College of 
Medical Genetics (ACMG), however, recommends only 59 
medically actionable gene variants for return (ACMG Board 
of Directors 2015) and assigns the researchers an obligation 
to actively screen for and report pathogenic variants (Mack-
ley et al. 2017). The European Society of Human Genetics 
(ESHG) endorses a more cautious approach, recommending 
the targeted sequencing and analysis of genetic data in line 
with the primary research goals (Matthijs et al. 2016; Mack-
ley et al. 2017), in order to keep the number of unsolicited 
results as low as possible (van El et al. 2013).
Second, it is not always clear who should have the respon-
sibility to feedback the results, particularly in the context of 
data sharing and biobanks. There is a lack of consensus as 
to whether it should be the original researcher, the biobanks 
providing the data, or the current researcher who has respon-
sibility for returning unsolicited results created by others 
(Bledsoe et al. 2013).
Third, there are concerns as to the potential liability of 
researchers. In cases of non-disclosure, this may be as a 
result of failure to disclose results that potentially could have 
prevented harm (McGuire et al. 2014). In cases of disclo-
sure, this may arise due to the harm arising from disclosure 
of distressing genetic results.
Outside of the possibility legal responsibilities and liabili-
ties of researchers, learning their carrier status of a genetic 
variation and the possibility of developing a disease may 
have severe negative psychological and social consequences 
for participants (Bredenoord et al. 2011). Therefore, it is 
essential that participants are informed about the possi-
ble implications of their decisions to be fed back genetic 
results. Providing comprehensive and easily understand-
able information is critical to enable truly informed deci-
sions by participants on this matter. An additional layer of 
complexity is that the unsolicited results may relate not only 
to the research participant, but also their family members 
who may be potential carriers of the genetic mutation (Wolf 
et al. 2015).
In light of these concerns, in order to return any results, 
a comprehensive strategy must be put in place allow-
ing a responsible disclosure process. This will impact the 
informed consent process, have implications on the manage-
ment of re-contact of participants, require clinical valida-
tion of research results to be conducted, and necessitate the 
provisions of genetic counselling (Budin-Ljosne et al. 2016).
To meet these demands, additional resources will need to 
be allocated, a requirement many research funders may be 
unwilling or unable to finance (Budin-Ljosne et al. 2016). 
Costs of disclosure and who holds the burden of return are 
a serious issue to take into consideration when discussing 
the RoRR. In fact, the responsibility for allocating additional 
resources could fall to the local healthcare systems. In recent 
years, an increasing number of national healthcare organiza-
tions have invested in large-scale genome sequencing pro-
jects. Stark et al. (2019) and Manolio et al. (2015) map an 
extensive list of publicly funded genomic-medicine initia-
tives around the globe and some provide genetic counsel-
ling to their participants. Despite this, it is still questionable 
whether national healthcare services should, are willing, and 
are able to take over the communication of genetic research 
results to research participants. Issues such as the lack of 
infrastructure to process the genetic data, limited capacity 
and capability of clinical staff to interpret genetic results, 
uncertain clinical utility and validity of genetic results, and 
extensive additional costs will need to be overcome (Stark 
et al. 2019; Manolio et al. 2013). Thus, Ginsburg (2014) 
argues that the majority of healthcare systems around the 
world are not ready yet to translate results of genetic research 
into practical healthcare.
In light of these legal, ethical, financial and organiza-
tional challenges with communicating genetic results, it 
is unsurprising that policy makers are grappling with the 
development of policies and best practice (Knoppers et al. 
2015; Fiallos et al. 2017; Budin-Ljosne et al. 2016). In the 
absence of guidelines, most studies still decide not to return 
any individual research results (Heaney et al. 2010). Studies 
that opt to feedback genetic results will thus need to design 
their own study-specific return policy after due consideration 
of the aforementioned ethical and legal responsibilities. A 
patient-centered approach guided by participatory research 
such as community-based participatory research (CBPR) 
that focuses on empowering participants and giving them 
an active role in developing research processes should be 
adopted (Institute of Medicine 2013; Wells and Jones 2009; 
Chung et al. 2010; Anderson et al. 2012; Kost et al. 2017; 
Vayena and Tasioulas 2015). This is particularly impor-
tant in developing a returns policy where new sequencing 
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techniques may unveil a great number of relevant variants 
in healthy cohorts.
The CHRIS study
The Cooperative Health Research in South Tyrol (CHRIS) 
study is a healthy cohort study that explores the genetic and 
molecular foundation of cardiovascular, metabolic, neuro-
logical and psychiatric diseases in the general population of 
the middle and upper Vinschgau/Val Venosta in South Tyrol, 
Italy. The CHRIS study is a population-based study with a 
longitudinal outlook, which started in 2011 (Pattaro et al. 
2015). The baseline study phase was completed in December 
2018 with over 13,000 participants. The follow-up phase, 
in which all participants will be re-invited, started in 2020. 
Until now, the quality of the genotyped data derived from 
the CHRIS study did not allow the clinical validation of any 
genetic results. Therefore, the policy of the baseline study 
regarding genetic results neither foresaw an active search 
for known diagnostic loci nor foresaw a general return of 
individual genomic results to research participants. This was 
communicated to participants before and during the CHRIS 
study. From the beginning, it was explained that the return 
of individual genetic results was generally not foreseen and 
that the researchers of the CHRIS study are not actively 
looking for diagnostic variants. It was also specified that 
the research of the CHRIS study is experimental and that 
it is highly unlikely that relevant individual genetic results 
will be found. This was communicated in a participant bro-
chure and a video as an integral part of the informed consent 
process. After watching the video, participants were asked 
to indicate their preference on re-contact if, in exceptional 
cases, unsolicited results were discovered. Participants could 
choose between one of 4 options: (1) to be contacted if any 
results were discovered; (2) to be contacted only if treatment 
options are available; (3) to be contacted if family members 
might be affected; or (4) never. During the baseline phase, a 
majority of 88% of participants opted for re-contact in any 
case and less than 1% for no re-contact at all.
To prepare for the cases of unsolicited results during the 
baseline study, the CHRIS study protocol adopted a strategy 
that established a committee consisting of the researchers 
involved in the analysis of the genetic data, the principal 
investigator of the specific study, members of the genetic 
counselling group from the local hospital of Bolzano, the 
President of the ethical review board and other members, 
depending on the trait. The committee would evaluate if the 
found results are clinically valid and actionable. Next, the 
participants’ consent form would be assessed to determine if 
they gave their permission to be contacted about individual 
genetic results. Following this, if the Committee decided that 
the results are to be returned, the genetic counselling ser-
vice would invite the affected participants for an individual 
consultation and perform clinical sequencing to reassess the 
found genotype. Any costs for the counselling procedure and 
further tests or treatment would be met by the local health-
care system. Until now, no results have met the threshold to 
be discussed within the committee.
The return policy for the baseline phase of the CHRIS 
study was developed by Deborah Mascalzoni after consulta-
tion with the local genetic counselling service. The policy 
was innovative when it was formulated in 2011 as very few 
genetic studies included the return of any genetic results in 
their study policies. Since then, there have been consider-
able changes in ethical best practice. Furthermore, due to 
increasing research on CHRIS data and growing knowledge 
about the significance of genetic variants, we expect to be 
confronted with an increasing number of relevant individual 
genetic research results soon. A revision of the return policy 
was then considered to be necessary. As part of this revi-
sion, we sought to gain insight into the concerns, needs and 
wishes of CHRIS research participants regarding the return 
of individual genetic results. As the return strategy of the 
baseline phase foresaw that the local genetic counselling 
service would take over the necessary clinical validation and 
initial communication of the genetic results and the medical 
consultation, the insights of genetic counsellors were sought. 
Additionally, we also strove to understand the concerns of 
local general practitioners (GPs) and their perception of 
practical challenges. In South Tyrol, an area characterized 
by small villages and mountain agriculture, the population 
still has a strong trustful relationship with their local GP. It 
is expected that many participants receiving genetic results 
will communicate these results to their GP and seek their 
advice. Thus, it was necessary to assess how best to inte-
grate them in the planning process, evaluate their needs and 
wishes regarding information and potentially education in 
the return of results. This paper reports on the findings of 
this research and will be used to inform the revision of the 
CHRIS returns policy.
Methods
This was a qualitative research study involving face to face 
interviews with 20 CHRIS research participants (out of more 
than 13,000), 3 GPs (out of 16 working in the area involved) 
and the head of the only genetic councelling unit in south 
Tyrol. This unit is the one that would be involved in the 
RoRR if performed. During the baseline study, participants 
were asked if they would be willing to take part in an addi-
tional interview regarding the return of individual genetic 
results. Out of the volunteering participants, a purposive 
sample (Neuman 2011) was selected, ensuring gender-bal-
ance and covering different age groups. The interviews were 
continued until no new arguments concerning the return of 
 Journal of Community Genetics
1 3
results arose and were conducted on 5 different days between 
October 2017 and February 2018 with 11 female and 9 male 
participants. The youngest interviewee was 18, while the 
oldest was 76 years old.
This study was reviewed and approved by the “Comi-
tato etico della provincia di Bolzano SABES” as part of the 
Cooperative Health Research in South Tyrol (CHRIS) study.
Data collection
Interviews with CHRIS participants
During the baseline study, a general written consent was 
obtained for the participation in the CHRIS study compris-
ing the conduction of interviews. In addition, participants 
were asked for their verbal consent to audio record the 
interview.
Prior to starting the interviews, participants were invited 
to complete a short questionnaire, collecting personal infor-
mation and asking for a self-evaluation of their knowledge 
about genetics. Additionally, the questionnaire comprised 9 
statements on inheritance and the development of genetic 
diseases, which had to be rated true or false. These, in addi-
tion to the self-evaluation questions, were included to assess 
participants’ level of genetic education as it might correlate 
with their opinion on receiving genetic results.
During the interviews, participants were presented with 
three examples of hypothetical individual genetic results 
that could potentially emerge through the CHRIS study or 
follow-up studies: breast cancer, Parkinson disease, and 
Huntington disease. The examples were carefully selected, 
based on a literature review and under consultation with 
geneticists at the Institute of Biomedicine, Eurac, in order 
to represent three different typologies to better illustrate the 
great diversity of genetic results regarding their informa-
tive value on health/life implications, their medical utility, 
and actionability. The examples showcase the differences of 
genetic variants in several characteristics, namely, the risk 
of developing the disease due to the genetic mutation, the 
availability of preventive measures and medical treatment 
options, the curability and potential lethality of a disease, 
and the age of onset of the disease. Table 1 presents the 
different expressions of characteristics for each genetic vari-
ant. Table 2 contains the translated information provided to 
the interview participants about the nature of genetic results 
and about each potential genetic finding and an introduction 
given. Participants were encouraged to ask questions in order 
to help them properly understand the different examples.
In case participants asked for more or different exam-
ples of potential genetic results, two additional examples 
had been prepared: malignant hyperthermia (MH) and rest-
less legs syndrome (RLS) (Tables 3 and 4). These examples 
were chosen because they highlight additional characteristics 
Table 1  Characteristics of main examples of genetic results
Breast cancer Parkinson disease Huntington disease
Genetic mutation Autosomal, dominant mutation 
BRCA1 and BRCA2
Low penetrance, recessive, heterozy-
gous mutations in the parkin gene 
(PRKN)
Autosomal, dominant mutation in the 
Huntingtin gene (htt). Monogenic 
disorder
Risk (of developing the 
disease due to the muta-
tion)
Significantly increased risk of 
38–87%
Slightly increased risk (3–7%) High risk (100%)
Prevention possibilities • Regularly precautionary medical 
check-ups
• Precautionary mastectomy
• Early recognition significantly 
increases the chances of complete 
recovery
• Late recognition, in which metas-
tases have formed in other body 
regions prohibits complete recovery
No preventive measures available No preventive measures available










Disease onset Earlier than without mutation Adult onset at an average age of 
60 years
Adult onset between 40 and 50 years
Cure Sometimes possible No cure No cure. Premature death
Severity of the disease Potentially lethal Non-lethal Lethal (premature death after 
15–18 years after onset)
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Table 2  Information provided orally to participants on examples of potential genetic results (translated from German)
Example Description
General introduction (given directly 
before presentation of examples)
“At this point in time you will only receive clinical results from the CHRIS study, which are among others 
your ECG, blood results and your Body-Mass-Index. This however might change in the future. With 
advancing research, we expect that more individual genetic results will arise, that might be relevant for 
our participants. Therefore, we are trying to figure out what kind of genetic results might be interesting 
to our participants. And this is also why we would like to know more details from you on what kind of 
genetic results you would like to receive
Generally, the genetic research of the CHIRS study is still experimental and thus we do not expect to 
detect many results, that have a direct medical use for a single research participant. However, with 
increasing research on the collected data it might be the case, that now or in the future, results are found, 
that are indeed relevant for the health of our participants
It is important to know that genetic results are can be very diverse. Only a very small number of results 
can predict if someone will develop a disease with high certainty. A much larger number of results will 
only be able to indicate an elevated risk to develop a certain illness
To make it easier for you to understand what genetic results are, I will present you with three examples 
of potential genetic results. These examples are very different and are representing different types of 
genetic results. After each example, I will ask you what you think of the result and if you would like to 
receive it. If you have any question during my explanation, please do not hesitate to interrupt me
I want to stress: These examples are presented in a simplified manner and we are not going to much into 
scientific details. Furthermore, the decision you are making today is not binding for any actual genetic 
results from the CHRIS study
Do you have any questions so far?”
BRCA1/BRCA2 The first example are two genetic variants, that increase the risk of developing breast cancer. Approxi-
mately 60 to 80 out of 100 women, that have one of these genetic variants, will develop breast cancer 
at some point throughout their life. Not only women also men can develop breast cancer due to these 
variants. However, they have a lower risk than women. *(In men it is only 20 out of 100). The risk of 
developing breast cancer due to these genetic variants is relatively high, however it is not 100 percent. 
This means, that a person that has this genetic variant might stay healthy throughout their entire life. 
Moreover, also a person, that does not have the genetic variant, might still get breast cancer
If one of these genetic variants has been detected, it is possible to do regular precautionary medical 
check-ups. This will facilitate the recognition and treatment of a tumor at an early stage and increase 
the chances of a complete recovery significantly. Another possibility is to have a precautionary breast 
removal on both sides. *(As a man, you might not feel too concerned about breast cancer. However, 
keep in mind that breast cancer is only an example representing similar kinds of results. Thereby I mean 
genetic variants that lead to a high risk of developing a serious disease for which precautionary meas-
ures are available.)
The chances to pass the genetic variant on to children are 50 percent. This does not mean that children 
will develop the disease, but that they can inherit the elevated risk of developing breast cancer
Do you have any questions about this example?
*Information in brackets has only been provided to men
Morbus Parkinson The second example is a genetic variant, that increases a person’s risk of developing Parkinson Disease. 
Have you heard of the Parkinson’s Disease before? (pause for answer)
Parkinson is a disease of the central nervous system. One of its best-known symptoms is heavy tremor. 
Other symptoms are muscle rigidity and cognitive impairments
So far, several genetic variants have been identified, that increase the risk of a person to develop Parkinson 
Disease. However, the augmentation of the risk is very low. This means the chance of actually develop-
ing Parkinson Disease because of one of those genetic variants is very low. Actually, the risk is only 
slightly higher than of any other person of the population to develop Parkinson Disease. Moreover, most 
people that develop Parkinson Disease, do not have any of the known genetic variants
In contrast to breast cancer there are no precautionary measures that can be taken, to prevent the develop-
ment of Parkinson Disease. The outbreak of the disease cannot be prevented, and treatment is only pos-
sible once the disease manifested itself. Until now Parkinson Disease cannot be cured. However medical 
treatment can alleviate the symptoms significantly, and the progress of the disease can be delayed. Also, 
it is important to know that Parkinson Disease does not necessarily lead to a premature death
The chance to pass the genetic variant on to children is 50 percent. Like for breast cancer, this does not 
mean that children will inherit the disease, but that they might inherit an elevated risk to develop it
Do you have any questions about this example?
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of genetic results. Potentially lethal complications during 
medical interventions under anesthesia cause MH that can 
be entirely prevented by using alternative anesthesia if the 
genetic predisposition is known. This high benefit of know-
ing one’s carrier status paired with the low chance of detect-
ing it without genetic testing made MH a good example for 
those participants skeptical of receiving any genetic results. 
RLS was chosen because in contrast to the other examples 
of potentially very severe diseases, it represents a non-lethal 
illness for which no preventative measures exist. Addition-
ally, the symptoms of the disease can be strongly improved 
symptoms once they occur. The additional examples were 
also prepared in case a participant had personal experience 
with one of the main examples and their decision thereby 
biased and not based on the general characteristics of the 
genetic result. During all interviews, two researchers were 
present (M.K. and D.M). This approach was chosen, as it 
proved useful for one interviewer to ask the questions and 
for the other to follow the conversation and add additional 
queries when statements seemed to be unclear or ambiguous.
The questions focused on four main topics: (1) the par-
ticipants’ motivation for their participation at the CHRIS 
study; (2) their knowledge of genetic diseases; (3) their 
preferences and concerns regarding the return of individual 
genetic results; and (4) their wishes regarding practicalities 
of the returning process. These topics were developed based 
on literature review that lead to a first publication (Budin-
Ljosne et al. 2016) and empirical research results from an 
unpublished study with local GPs (D.M.) identifying current 
challenges impeding the communication of genetic results 
to research participants. The interviews lasted between 20 
and 40 min and were held in German, the main language 
spoken in the region.
Interviews with general practitioners and a genetic 
counsellor
The GPs and genetic counsellor interviews focused on the 
following themes: (1) expertise and experience in commu-
nicating genetic results in their everyday work; (2) opin-
ions on returning genetic results to CHRIS participants; 
(3) opinions on an active search for diagnostic variants; 
(4) the potential role of GPs/genetic counselling services 
Table 2  (continued)
Example Description
Chorea Huntington A very different result is a genetic variant that causes the Huntington Disease. Have you ever heard of this 
disease? (pause for answer)
Huntington Disease is a disease that is caused by a single genetic variant. It damages the neural cells in 
the brain, which leads to the development of motoric and psychological problems like involuntary move-
ments, alterations of the personality, depression, dementia and psychosis. In the final stage of the disease 
the affected persons are confined to their beds and completely dependent on the help of others. The 
disease usually sets on around the age of 45. The disease is not curable and always leads to a premature 
death
The genetic variant causing the disease can be detected through a genetic test. A person that has this 
genetic variant will always develop the disease. Moreover, the genetic variant can be passed on to one’s 
children. The chances for children to inherit the variant is 50 percent. If a child has inherited the variant 
it will develop the disease at one point in their life
Do you have any questions about this example?
Table 3  Characteristics of alternative examples of genetic results
Malignant hyperthermia Restless legs syndrome (RLS)/Willis-Ekbom disease
Genetic mutation Autosomal, dominant mutation
RyR1 or CACNA1S
Polygenic disorder. Various variants contribute to the phenotype
Risk (of developing the disease due 
to the mutation)
High risk (50%) Slightly increased risk
Prevention possibilities Usage of alternative anesthetic agents or 
muscle relaxants
No preventive measures
Treatment possibilities If recognized promptly, treatable. Other-
wise possibly lethal
Lifestyle change and medication can alleviate symptoms
Disease onset Anytime From childhood to over 90 years
Cure No cure No cure
Severity of the disease Potentially lethal Non-lethal
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in the return process. The participants were also presented 
with the same three examples of potential genetic results 
and inquired on their opinion on communicating these 
results to research participants.
All interviews were conducted in German, except the 
one with the head of the genetic counselling service, 
which was conducted in Italian. After obtaining verbal 
consent, the interviews, which lasted between 30 min and 
1 h, were audio recorded. One interview with a GP was 
conducted via telephone with only one researcher (M.K.), 
while all others were held face to face with two research-
ers (M.K. and D.M.).
Data management and analysis
The interviews were audio recorded, transcribed verbatim, 
and coded thematically using Atlas.ti (M.K.). Both M.K. and 
D.M. independently coded the transcripts and any discrep-
ancies were discussed. The coding was then revised as was 
the codebook (M.K.) (Neuman 2011; Flick 2014; Belotto, 
Table 4  Information provided 
orally to participants on 
alternative examples of potential 
genetic results (translated from 
German)
Example Description
Malignant hyperthermia Another example for a possible genetic result is 
Malignant Hyperthermia
Malignant Hyperthermia is a condition that 
can lead to severe complications if certain 
anesthetics or muscle relaxants are given 
to a person, for example in the course of an 
operation. These complications can lead to 
organ failure and end in death. However, if 
the cause of the complication is identified 
correctly measures can be taken that to cure 
the symptoms and death
In case it is known that a person has the genetic 
variant responsible for Malignant Hyper-
thermia, alternative anesthetic agents will be 
used, and the complications can be prevented 
altogether
The chance to pass the genetic variant on to 
children is 50 percent. This does not mean 
that children will inherit the disease, but that 
they might inherit the risk of developing it
Do you have any questions about this example?
Restless legs syndrome A further example for a possible genetic result 
is the Restless Legs Syndrome. The disease 
leads to the development of an unbearable 
urge to move your legs or sometimes also 
arms during rest or night-time. This often 
results in insomnia and sleep deprivation and 
can have negative effects on the mental and 
physical health of a person
Several genetic variants have been identi-
fied that increase the risk of developing this 
disease. However, not just genetic factors but 
also other factors like lifestyle or environmen-
tal factors can influence the development of 
the Restless Legs Syndrome
At the moment, the Restless Legs Syndrome 
cannot be cured but lifestyle changes and 
medication can significantly ease the symp-
toms. The disease can develop at any age
The chance to pass the genetic variant on to 
children lies between 50 and 60 percent. This 
does not mean that children will inherit the 
disease, but that they might inherit the risk of 
developing it
Do you have any questions about this example?
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2018). All analytical steps were performed in German, also 
for the Italian interview. Only the results of this study were 
translated into English for this paper.
Results
After being asked if they wanted to be informed about a spe-
cific genetic variant, should they be found to be a carrier, 17 
participants wanted to be alerted about the variants BRCA1 
and BRCA2, while 3 declined. In the event of mutations in the 
parkin gene, 7 individuals expressed the desire to be notified, 
10 decided against it, and 3 remained undecided. Nine partici-
pants asked for disclosure of the variant causing Huntington 
disease, while 11 did not wish to learn about it.
During two interviews, in which the participants did not 
want to be informed about any of the three presented genetic 
variants, the interviewers decided to present MH as an addi-
tional example. Both participants stated that they wanted to be 
notified if they had the variant related to MH.
In one interview, a participant stated that they did not want 
to be informed about variants related to Parkinson disease, as 
they had personal experience with the disease. The partici-
pant also did state that they would not want to be informed 
about any variant with potentially severe health implications, 
no matter the variant’s other characteristics. Following this, 
the interviewers decided to present the example of the restless 
legs syndrome (RLS), as it has similar characteristics to Par-
kinson disease (no, preventative measures, no cure) but with 
less severe health consequences. The participant wanted to be 
informed about RLS.
Disclosure—an intrinsic decision
The choices made by participants and the motivations behind 
them proved to be extremely diverse and highly personal. A 
common observation, however, was that participants wanted 
to make an autonomous decision regarding the disclosure or 
non-disclosure of their results. Some stated that they would 
feel betrayed or disappointed if results were available but not 
offered to them. Several participants felt that they have a right 
to be informed about available personal genetic results, even 
if it might be categorized irrelevant by researchers or genetic 
specialists. Participants felt that decisions on disclosure of 
results must remain with the individual and that these pref-
erences may change over time in accordance with their own 
preferences and changes in scientific knowledge.
Some participants allocated a clear responsibility to the 
study to inform and help study participants and therefore share 
results. However, some stated that the CHRIS study should 
serve the common good and therefore would understand if no 
results are offered due to economic limitations.
Decision factors for disclosure
Although factors affecting decision were highly personal, 
there were some common criteria. They were actionability 
of results, disease factors, and impact on genetic relatives.
Actionability of results
The medical actionability of genetic results played a cen-
tral role in participants’ decisions on disclosure. Partici-
pants were presented and discussed four subcategories of 
actionability:
The possibility to entirely prevent the onset of a disease;
The possibility to recover completely after the onset of a 
disease which cannot be prevented;
The availability of precautionary measures that cannot 
prevent the outbreak of a disease but facilitate early recogni-
tion and timely treatment and potentially cure;
The availability of medical treatment or lifestyle changes 
that cannot cure the disease but delay its progress or ease 
its symptoms.
Fear of experiencing anxiety was a cross-cutting argu-
ment against disclosure of results of all categories, while 
the key argument for disclosure was the possibility to take 
actions and the feeling of being prepared for the future. Par-
ticipants weighed these factors against each other in their 
decisions and made very diverse choices.
Possibility to prevent onset of a disease All participants 
wanted to be informed about results that could facilitate the 
complete prevention of the onset of an illness. These results 
were seen as a unique opportunity to take active measures to 
stay healthy and the probability to suffer from anxiety was 
evaluated as low.
Possibility to cure a disease Genetic variants that increase 
the risk of developing a disease which can be cured once 
it breaks out, but not prevented beforehand, led to diverse 
decisions on disclosure. Participants deciding for disclosure 
reasoned that because the disease was curable, they would 
not worry, but be able to inform themselves early on about 
risks and treatment options.
[…] you will be more attentive, if something is out of 
the ordinary. That you rather say, now I will let this be 
checked or so… Or otherwise maybe… ahm you will 
not pay attention to it and then it might be too late. 
(Participant 02).
Other participants saw no advantage in knowing these 
genetic predispositions because they cannot take any pro-
active measures before any symptoms show. They feared 
burdening their lives with unnecessary anxiety as the disease 
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might never break out, and if it did, they would still be able 
to undergo medical treatment and cure the disease.
No, I would not want that. As soon as it occurs, I 
will have to handle it, but I don’t want to know. […] 
Because maybe then in my fear…. I would live in fear 
it could be affected or I could get this disease and that 
I do not want because I still cannot do anything against 
it. (Participant 01).
Availability of precautionary measures to treat or 
cure Where results would enable participants to take pre-
cautionary measures that cannot prevent the disorder but 
lead to early detection and treatment, a number of par-
ticipants stated that knowing their results would motivate 
them to take precautionary measures or have regular medi-
cal check-ups. The possibility to act before a disease might 
break out as well as the fear of missing the chance of inter-
vening early enough led participants to decide for disclosure.
[…] If you know that, you might be more diligent with 
the check-ups. Otherwise you always think: ahh not 
me, or, yes yes I will do that sometime, or … exactly 
and I think if you know you are in this thing, that it 
could be…, I think you will be more diligent with the 
check-ups. You will say, yes ok now I will do this once 
a year. (Participant 02).
Others, however, feared they would burden their lives 
with stressful medical visits that will not be able to prevent 
the development of the disease. These participants felt that 
concerns on the suffering of anxiety outweighed the benefit 
of the limited actions available.
I would not make the test, because if I get it, I get it 
(breast cancer), and I don’t care if I have a higher risk 
or not. […] I would not … how do you say … visit 
the doctor more frequently, because I have it (genetic 
variant). I would not do it. (Participant 9).
All participants expected that results for diseases that can 
be eased through medical interventions but not completely 
cured will cause worries. However, some regarded the pos-
sibility to mentally prepare themselves for the consequences 
of a disorder as more valuable. They expected that the avail-
ability of medical treatment options would ease their worries 
and led them to decide for disclosure. One participant also 
explicitly stated that if traditional medicine cannot provide a 
cure, they would search for treatment or prevention options 
from alternative medical schools like traditional Chinese 
medicine.
… there are maybe people that, let’s say, sleep away, 
their life. And I think if someone has something like 
this (Huntington disease), then he can prepare himself. 
Also things like arrange things at home, like the last 
will, because I think later you cannot do this anymore. 
And things like that. Yes, I think that is important (Par-
ticipant 11).
Other participants felt that since no actions can be taken 
to prevent or cure the disease, knowing their genetic predis-
position was pointless. They feared such results would cause 
anxiety and thus lower their life quality. Moreover, they also 
expressed the concern that knowing their results might alter 
important decisions in their lives.
The difference is, you cannot do anything against it, it 
does not matter if I know it sooner or later, it is here 
when it is here. And because you cannot do much, I 
do not think it is like breast cancer, that is something 
else. Because there I can really say if I know it early 
on I can… I have a bigger chance to be cured. That is 
the difference yes. (Participant 5).
Disease factors
The characteristics of the genetic variant were especially 
important for participants’ decision on disclosure, namely, 
the risk or probability of actually developing a disease, the 
severity of the disease, the age in which the disease is most 
likely to develop, and the availability of alternative ways of 
diagnosis besides genetic testing.
Risk level The probability of developing a genetic disorder 
due to a certain genetic variant was relevant results that par-
ticipants requested in order to make their decision on disclo-
sure. The mutations in the parkin gene represent a very low 
risk of developing the Parkinson disease while the example 
of Huntington disease represented a high risk, as a mutation 
in the Huntingtin gene will always lead to the manifestation 
of the disease.
Participants who decided for disclosure of a low risk level 
result stated that they wanted to know any genetic results on 
their health, as it might be useful in the future.
Yes… I want to know everything, if that is possible. 
Even if it is not sure, that it will develop, but…yes. 
(Participant 14).
The main motivation for those wanting to know high risk 
level results was the desire to be able to plan their future and 
take the disease into account when making important life 
decisions. While some considered not working as hard as 
they do, others would rethink their family planning.
… I want to know it. In general, if I would have… so I 
can organize my life until it actually breaks out or first 
symptoms show. […] Yes, so I can still plan my life. 
Like go on holydays sometime and travel. Otherwise 
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I always postpone it and like this I could go sooner. 
(Participant 15).
Some participants argued that a high risk combined with 
the absence of medical interventions would be a motivation 
against disclosure. They felt a result like this would prevent 
them from living a full life in the present as constant worries 
for the future would prevail.
Disease severity Closely connected to risk level is the sever-
ity of a disease related to a certain genetic variant. Here, par-
ticipants differentiated between mild diseases that have a low 
impact on the utilization of resources, comorbidities, and 
mortality and severe diseases that have a high impact. Those 
asking for disclosure for results connected to mild diseases 
argued that they did not expect to suffer from anxiety upon 
learning of such results. Instead, they valued the opportunity 
to inform themselves about the disease and mentally prepare 
themselves before a potential outbreak.
Yes. You will always have a little bit of fear as well. 
But you may be able to do something if it breaks out, 
maybe you can alleviate it. (Participant 17).
Similarly, those asking for disclosure of results for a 
severe disease evaluated the chance to know their risk of 
developing a disease that might have a great impact on their 
life as favorable, because they wanted to be able to plan their 
life accordingly.
But yes… so you can take provisions and I think the 
earlier the better. You can also prepare mentally some-
how… (Participant 11).
Participants opting against disclosure for mild diseases 
as well as those deciding against results relating to severe 
diseases stated that they feared knowing their results would 
lead to anxiety. While the anxiety caused by variants related 
to mild diseases was evaluated as unnecessary since the dis-
ease will have relatively minor consequences for their lives, 
participants feared that the worries caused by severe diseases 
would affect their life choices in a negative way.
That you maybe will already fixate on it too much. 
Also I think you maybe already feel a tremor even if 
there is none. That is a shame if you already worry 
too early about something that probably or maybe will 
never come. (Participant 5).
Age of onset The age of onset of a disorder related to a 
genetic variant proved to be an influential factor for partici-
pants’ decision. Generally, participants rather wanted to be 
informed about diseases with an early onset. Illnesses that 
are estimated to only develop after the age of 60 were con-
sidered less relevant. However, participants expected that 
their preference will change over time and with advancing 
age.
(…) one should always be able to change one’s mind. 
[…] Because one will maybe be more adult and then 
one might have a different opinion. (Participant 9).
Some participants above the age of 60 indicated that they 
did not want to know any genetic results, even if the con-
sequences of a genetic mutation might affect them soon. 
They argued that genetic results are no longer relevant for 
them, but they participated mainly for the benefit of their 
descendants.
(…)Yes for my descendants. Because for myself it is 
not that important… let’s say it is important, but it 
does not benefit me anymore. The clinical exams yes, 
but the research results are for my descendants. (Par-
ticipant 3).
Chances for diagnosis Another interesting factor that 
emerged from the interviews was the question concern-
ing alternative possibilities for diagnosis. If obtaining the 
genetic results from the CHRIS study was the only chance 
for participants to receive a diagnosis, some wanted to be 
informed about results that had characteristics that would 
normally lead them to reject disclosure. The same applied 
also if getting a diagnosis would be possible but potentially 
very difficult or require invasive testing.
If there is no other way of identifying the disease, I 
would like to know. Otherwise not. (Participant 5).
Impact on genetic relatives
Another important decision factor was the significance of 
genetic results for participants’ children and relatives.
Heredity.
The heritability of a genetic defect greatly influenced the 
decision of participants that already had or planned to have 
children. Many participants wishing to have children in the 
future wanted to know their risk, as they did not want to pass 
on any disease to their children and would consider pursuing 
alternative family planning options.
Well then I would wonder if I even want to have chil-
dren, because it is an imposition. The children cannot 
decide if they want to have the gene. I think it is a little 
bit selfish if you then just… just make this decision for 
the children. (Participant 10).
Others, however, did not want that a mere risk to influ-
ence such an important life decision. Several participants 
demanded specifically not to be informed, as it might gen-
erate anxiety in their children or because they felt their 
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children had the right to decide themselves if they wanted 
to know such results once they are grown up.
No. Even if the kids are… (affected). I already have 
two children so… […]. I do not want to know that, no. 
Because there you see no chance somehow, that this 
can’t be or so. (Participant 04).
Affected relatives.
The prospect that other relatives might be affected by a 
genetic mutation was evaluated as a less decisive factor as 
the possibility of passing it onto their children. Many par-
ticipants felt that their relatives had to decide for themselves 
if they wanted to take genetic examinations and expressed 
uncertainty as to whether they would share their results with 
their family. However, certain participants that had experi-
ences with severe diseases in their family reported it would 
be important to share any results to enable their relatives to 
take appropriate action.
Participants’ misconceptions about genetic results 
in CHRIS
Throughout the interviews, two major misconceptions 
regarding the return of unsolicited results in the CHRIS 
study were identified.
Firstly, during the informed consent process of the 
CHIRS study, participants were informed that researchers 
are not actively searching for diagnostic variants. This fact 
was explicitly mentioned in the participant brochure, in the 
introductory video to the CHRIS study that all participants 
viewed prior to participating in the study, and in the consent 
form. It was also stated that in rare cases in which relevant 
results were identified during research, participants will be 
contacted according to their preferences indicated on the 
consent form. Despite this, many participants assumed that 
the researchers would actively look through their data to 
identify genetic variants that might lead to the development 
of a disease and they expected to be contacted in case rel-
evant results were available. This led participants to pre-
sume that if the CHRIS study did not contact them, no rel-
evant genetic mutations had been detected during the active 
screening.
Secondly, it was detected that while people were aware of 
the possibility to receive genetic results or even expected it, 
there was limited understanding as to the meaning of genetic 
results. During the interviews, participants expressed sur-
prise when the three examples of genetic variants and their 
health implications were presented to them. Participants 
stated that they were unsure of what genetic results are and 
that they were unaware of the broad range of possible results 
in terms of risk, the severity of potential health implication, 
and treatment possibilities.
The results from the questionnaire demonstrated that par-
ticipants have an average knowledge of genetics. Participants 
had to rate 9 statements on inheritance and the develop-
ment of genetic diseases true or false. In sum, participants 
answered 105 of 180 questions correctly and 44 incorrectly 
and 31 questions remained unanswered. Regarding their 
self-evaluation, 9 participants evaluated their knowledge on 
genetics as very low and 5 as low and 6 indicated to know a 
bit. None of the participants self-reported as having a good 
or very good knowledge. Also, in the questionnaire, the par-
ticipants expressed the feeling that their level of knowledge 
is either equal to the general public or lower. The high num-
ber of unanswered questions from the questionnaire and the 
low self-evaluation indicate that participants have a basic 
knowledge on genetics.
The opinion and role of general practitioners 
and the genetic counsellor in ROR
All GPs supported the return of genetic results as being use-
ful and a right of the participants but they also voiced several 
concerns. They were especially worried that genetic results 
might create fear and anxiety among their patients. Further, 
they were concerned that patients would misinterpret genetic 
results as a clinical diagnosis. They expressed concern on 
how participants might react, when learning about their 
elevated risk to develop certain diseases. They argued that 
as the general population has no experience in receiving and 
interpreting genetic results, they might be overwhelmed and 
over-interpret their predispositions. This might lead them to 
take unnecessary medical interventions. They emphasized 
that research results must be clinically validated before 
returning them.
At the moment I think so because the awareness of 
how to deal with such results is not very widespread 
yet. I think this will rather have a shocking effect… 
(General Practitioner 3).
Another concern voiced was that the genetic results about 
a person or a family being affected by genetic disorder might 
spread around the villages and cause social stigmatization. 
Therefore, the GPs stressed the need for utmost discretion 
when sharing genetic results.
… it is a small country and like I said, news travel fast. 
And then people are quick to say… oh in this family, 
they have this and that gen and so on… Honestly, I 
would be very cautious. Here you can easily stir up a 
hornet’s nest. (General Practitioner 2).
When confronted with the three examples of genetic 
results, the GPs had different opinions on what kind of 
results should be shared. There were particular concerns 
about genetic variants that only slightly increase the risk of 
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developing a disease, such as the variants described in the 
example of Parkinson disease. GPs feared that these results 
might cause unnecessary anxiety among their patients. In 
general, however, all GPs agreed that the participant should 
have the right to decide for themselves what kind of results 
they want to receive.
… The decision has to remain with the proband, with 
the human. He has to decide. No discussion. […] 
This is essential. The owner of the genetic data has to 
decide. Well the patient or the proband has to decide 
himself. I think we cannot make the decision for him, 
and we must not. (General Practitioner 1).
Regarding their own role in the returning process, the GPs 
stated that they did not feel confident to advise their patients 
on genetic results, as currently genetics plays a minor role 
in their daily work and they lack the necessary expertise. 
While the physicians would like to be informed subject to 
the consent of the participant, about potential genetic results 
of their patients, they rather see their role in encouraging 
patients to seek a specialist’s advice or undergo the neces-
sary examination or treatment.
… I am a general practitioner and I have to take care 
of so many things. If this is getting so detailed, I would 
refer to the colleagues, the specialists that work in this 
field. […] Well I see our role in supporting the patients 
as good as possible and also in encouraging them to 
take further steps. (General Practitioner 2).
This is in contrast to the views of many participants who 
reported having a strong personal and trusting relationship 
with their general practitioners. Some even preferred to be 
informed about genetic results by their physician instead of 
a genetic specialist and others demanded that their results 
would also be sent to their family doctor after a consultation 
with a specialist.
Rather the general practitioner because you know 
him better and longer. And also the doctor knows the 
patient already for a long time. In the hospital it is 
more anonymous, isn’t it? You are not there often. I 
would say rather the general practitioner. (Participant 
6).
The genetic counselling service in Bolzano supported 
the return of genetic results to participants and stressed the 
importance of an autonomous decision on disclosure by the 
participants that reflects the genetics unit approach to genetic 
results. They also thought that the cohort could lead to joint 
projects on several genetic-related disorders that could 
potentially lead in collaboration with the healthcare sys-
tem to preventive health projects. For this type of potential 
development, appropriate understanding and consent of the 
individuals would be paramount. However, concerns were 
raised regarding the enormous workload that might arise 
for their rather small team of only 4 counsellors. The physi-
cians as well as the genetic counselling group stressed that 
participants cannot be left alone with their results but that a 
close collaboration between them and the CHRIS study as 
well as further specialists and psychologists must be built in 
order to responsibly advise participants.
Discussion
In this study, we sought to investigate whether we should 
return results to research participants, and if so, how should 
such a policy be designed. Our findings echo other stud-
ies that have shown that a majority of research participants 
would like to receive individual genetic results (Bollinger 
et al. 2012; Facio et al. 2013; Allen et al. 2014; Middleton 
et al. 2016; Jamal et al. 2017; Yamamoto et al. 2017, 2018). 
This study also highlights that research participants want 
to make an independent decision on the disclosure of their 
genetic results. As the first study that unpacked respondent 
choices and decision-making based on the four categories 
presented, it demonstrates that the amount and kind of feed-
back that participants want to receive are very diverse and 
based on intrinsic individual motivations that can be part due 
to the particular genetic condition.
Most research studies and biobanks are hesitant to offer 
a broad range of genetic results (McGuire et  al. 2014). 
Concerns have been expressed that returning results with 
uncertain clinical significance or without clear medical 
actionability could cause distress and psychological harm 
to participants as they might be unable to correctly interpret 
results, overestimate their implications, and even undergo 
unnecessary medical treatments (Lázaro-Muñoz et al. 2017). 
Dresser has contested this view arguing that there is limited 
research on this point and thus insufficient evidence to refuse 
to feedback results due to concerns regarding the potential 
psychological impact (Dresser 2014). However, to avoid 
liability, most researchers limit their output to the genetic 
variants specified in professional guidelines or evaluation 
mechanisms that have been developed in order to assess the 
relevance of results for research participants (ACMG 2015; 
Berg et al. 2013, 2016; Cassa et al. 2012; Matthijs et al. 
2016). All these recommendations state clinical validity 
and medical actionability as the main criteria for returning 
genetic results (Lázaro-Muñoz et al. 2017) and do not con-
sider participant autonomy and their preferences.
The findings of our study indicate that there is a discon-
nect between patient preferences and the narrow margin of 
results researchers deem appropriate for sharing. Research-
ers and biobanks rely on “clinical utility” (i.e., whether the 
results can improve a clinical outcome), whereas our partici-
pants’ motivations rest more on “personal utility,” echoing 
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the findings of Urban and Schweda (2018). Personal util-
ity refers to non-clinical uses of the results such as feelings 
of control and planning for the future (Kholer et al. 2017). 
However, our study indicates that personal utility and clini-
cal utility are very much intertwined and provide empirical 
evidence for this need for a shift towards reporting results 
that have personal utility (Thorogood et al. 2019). Personal 
decisions are very much linked to clinical outcomes and both 
must be factored in when deciding on feedback of results.
Having identified that our participants have a preference 
for the return of results, the CHRIS study now needs to 
determine the process in case of results and importantly who 
should be responsible for returning to the participant. We 
need to be mindful that the main motivation for those against 
feedback was the expectation that knowing certain genetic 
results will lead to anxiety, reduce their quality of life, and 
negatively affect their life decisions. The interviewed GPs 
and the genetic counsellor also expected that sharing genetic 
results might lead to worries and anxiety among partici-
pants, as they have no experience interpreting and dealing 
with genetic results. The GPs especially feared that without 
adequate support and counselling, receiving genetic results 
might cause harm for the participants. Due to their time con-
straints and limited expertise on genetic results, the GPs see 
their role as encouraging participant to seek a specialist’s 
advice. Thus, the responsibility should not fall to GPs but 
genetic counsellors, who have the necessary knowledge and 
experience to address participants’ concerns. Tied up with 
this is the complex question of whether feedback of results 
should be classed as a responsibility of research institutions 
or general responsibilities to research participants involving 
public health. Resources and expertise available will impact 
the ability to return results, but owing to the strong prefer-
ences of participants to return results, researchers must fac-
tor this into the design of a study and facilitate the develop-
ment of a policy on this topic.
Having unpacked the findings in the study, the CHRIS 
study set up a collaboration with the local healthcare sys-
tem and the genetic counsellor unit. A joint committee com-
prising of ethics board members, researchers, and genetic 
counsellors will meet ad hoc to assess the ROR cases as 
they arise. We decided to integrate four examples of genetic 
results into the consent process of the follow-up phase of the 
CHRIS study: breast cancer, Parkinson disease, Hunting-
ton disease, and malignant hyperthermia. Participants will 
receive information on these four examples through different 
channels. With their invitation to the second phase of the 
study, they will receive a brochure explaining the examples 
and there will be additional information on the website of 
the CHRIS study. On this website, four videos (in German 
and Italian) are also available, in which doctors from the 
local genetic counselling service explain the four examples. 
When coming to the CHRIS center, participants will have 
the chance to watch an introductory video, explaining the 
second phase of the study. In this video, a brief summary of 
the examples and their main characteristics will be given. 
After watching this video, all participants will be asked to 
indicate for each example, whether they want to be informed 
or not.
There is now a growing consensus that there is a legal and 
ethical obligation to inform participants about the possibil-
ity or not to receive genetic results from a study (Ralefala 
et al. 2020). Some results that could be life saving (such as 
the MH) or actionable within existing healthcare pathways 
(BRAC 1 and 2) if known and available should be returned.
Our study provides an empirically tested procedure to 
be followed in designing a returns policy. This process can 
equally apply to biobanks and research projects that are look-
ing to shift from a “no-return” policy to a return of results 
policy or a mixed situation and those looking to design an 
ad hoc returns policy at the outset of their study. For those 
developing such a policy, we offer four recommendations.
First, although CHRIS has adopted a patient-centric 
approach that requires an assessment of patient preferences 
at all stages of the research (Pattaro et al. 2015), the start-
ing premise should be if participants want results returned 
and not how or what results should be returned. Starting 
from this point ensures that a policy is participant and not 
researcher led.
Second, when participants indicate a preference to know, 
researchers have a responsibility to develop a policy at the 
outset, in line with participant views. The factors affecting 
participants’ desire for results to be returned should guide 
the policy development and not the type of results to be 
returned. Focusing a policy on the type of results fails to 
consider the other factors behind participant decision to 
receive results. Thus, the current approach of the ACMG 
and ESHG is thus too narrow in focus.
Third, participants are likely to have limited knowl-
edge on genetic results. An important aspect in designing 
a responsible disclosure process for genetic results is to 
provide easily accessible and understandable information 
on all the identified factors that influence participants’ 
choices. Providing different examples for genetic results 
proved to be extremely helpful in facilitating participants’ 
comprehension.
Fourth, the development of this policy must also involve 
local genetic counsellors and representatives of the local 
healthcare system. This will enable the identification of 
who best to feedback results in line with the expertise 
and resources available to be integrated in the healthcare 
pathway.
Finally, the development and possible implementation of 
a policy must be budgeted for. Costs associated with the 
development of a policy include stakeholder engagement 
and the development of any necessary educational material. 
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Educational material will also need to be provided during 
the consent process that informs participants about the return 
of results policy.
The financial implications of a policy will depend upon 
whether the results will be actively searched for or if only 
research results found because of specific inquires will be 
returned. The costs of appropriate genetic counselling ser-
vices that could be paid out of research funds or covered 
through the local healthcare system also need to be con-
sidered. This important factor points to the need for early 
discussion and development of a policy.
Limitations
Reporting numbers in qualitative studies is controversial 
(Maxwell 2010). While some argue that numbers allow for 
precise description and thus increase the meaning of key 
findings, others fear they can (even unconsciously) lead to 
a false sense of generalizability of the results and imply the 
picture of a measurable reality (Neale et al. 2014). For this 
study, it must be stressed that due to the low number of par-
ticipants, no conclusions about the prevalence of opinions in 
the CHRIS population can be drawn. The aim of this study 
was to collect as many different opinions and arguments as 
possible but not to assess their prevalence.
Conclusion
This study aimed to inform the update of the policy on 
the return of genetic results to research participants of the 
Cooperative Health Research in South Tyrol (CHRIS) study. 
Through qualitative face-to-face interviews, we investigated 
the concerns, needs, and wishes of research participants, 
local general practitioners, and the local genetic counselling 
service regarding the return of individual genetic research 
results. Our findings reveal that participants want to make 
autonomous decisions regarding the return of their genetic 
results. However, we were able to identify several common 
criteria influencing research participants’ decision on disclo-
sure, providing easily comprehendible information on these 
factors is crucial to enable participants to make an informed 
and autonomous decisions. Moreover, the expectation to 
suffer from anxiety has been identified as main reason why 
research participants decline genetic results. This fear needs 
to be addressed by setting up a responsible communication 
process with appropriate genetic counselling in place before 
any results can be shared. Thereby, local general practition-
ers can only take over a limited, supporting role as they do 
not have the necessary genetic and psychological expertise.
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